We are in a moment of vast potential in life sciences—of diversified investments, breakthrough discoveries, and rapid expansion of therapeutics into new modalities and platforms. And AI is increasingly enabling data-driven decision-making across the product life cycle, from AI-supported drug candidate selection to real-time clinical trial site monitoring.
However, overall industry productivity—whether measured in terms of speed, cost-effectiveness, or ROI—has been stagnant for decades. While there are undoubtedly multiple causes of that stagnation, our experience suggests one cause is that biopharma has largely failed to reinvent its talent model to meet the challenges and opportunities of a rapidly changing biopharma ecosystem.
Leaders want to deliver on the promise of emerging knowledge but often struggle with a lack of internal alignment, including different assumptions about the shape of the future R&D portfolio, reactive resourcing, and unclear long-term talent needs. Indeed, many biotech and pharma companies today are asking themselves the following questions: What capabilities are key to innovation? How should we source or build these capabilities? And how can we attract and retain the necessary talent?
To better understand what life sciences companies are looking for and how the makeup of the workforce is evolving, we analyzed nearly one million LinkedIn job listings for R&D roles posted between 2020 and 2024 from about 150 organizations. From those same companies, we also evaluated about 300,000 LinkedIn profiles of R&D employees in 2023 and about 350,000 profiles in 2024. The results paint a picture of talent supply and demand in the industry. Furthermore, we surveyed about 700 R&D professionals to understand workers’ current sentiments (see sidebar, “About the research”). The rest of this article explores our findings and what they mean for organizations looking to build a distinctive talent model that drives R&D success.
Building a talent model for R&D success
Organizations have been largely relying on external recruiting to evolve their people model, but they need a more holistic solution. To build a distinctive talent model that drives R&D success, leading life science organizations should ask the following questions:
Do we have the right workforce for the future? Strategic workforce planning is essential to get the right talent in the right place to meet the demands of the evolving R&D portfolio, thereby positioning organizations for sustained success in a competitive landscape. Dynamic organizations proactively consider and define future demand for capabilities and roles based on the evolution of the portfolio. Given that capabilities where demand is similar to supply will likely face heightened competition for talent, a comprehensive approach is needed to measure and secure these critical skills. This includes sourcing specific capabilities for emerging modalities, such as cell and gene therapy, and ensuring the company has the necessary expertise in foundational skills, such as IT infrastructure and experience design.
Do we have the right elements to sustain this workforce? By offering clear, achievable career trajectories and fostering a culture of continuous learning and development, organizations can significantly enhance employee satisfaction and retention, ensuring that the workforce is equipped with the necessary skills and experiences to support the future R&D portfolio. Companies could embed a compelling employee value proposition (EVP) for priority capabilities and roles into both attraction and retention tactics. This EVP should be a pitch for working at the company that highlights great leaders, a great company, a great job, and great rewards. A strong EVP considers both current and future talent needs, emphasizing opportunities for growth, recognition, and supportive leadership. Biopharma companies can be highly transparent about what their ambitions are and demonstrate how a specific job profile can contribute to both making biopharma R&D faster, better, and cheaper and finding the right patients for medicines.
What is our fit-for-purpose strategy to build this workforce? Biopharma companies need to invest in programmatic and comprehensive learning journeys that move away from episodic interventions and to continuous learning. This involves coaching managers on the required capabilities: providing clarity, empowering and challenging their teams, fostering collaboration, and supporting the whole person. Managers must be held accountable for their role in developing talent. Additionally, empowering R&D professionals with learning tools and access to experts can significantly enhance their ability to take ownership of their development. By integrating tailored learning based on desired skills, external learning opportunities, and ongoing feedback and coaching, organizations can create a robust development ecosystem that motivates and equips the workforce for future challenges.
What environment will enable our workforce to thrive? Setting up cross-functional teams is crucial for breaking down silos and enhancing collaboration within organizations. Organizations must identify and set up specialized, high-performing teams tasked with leading the charge on critical projects, such as for new therapeutical approaches. These teams can clarify roles, mindsets, and accountability, thereby ensuring that collaborative efforts are both effective and aligned with innovation goals. Simplifying decision-making processes is also essential to overcoming the perceived bureaucracy and slow execution speeds that plague R&D in comparison to the broader life sciences sector. According to our research, R&D is perceived as 1.5 times more bureaucratic and has a perceived 1.1 times slower execution speed than the combined pharmaceutical and medtech averages. To achieve this, organizations must optimize their organizational structure, behaviors, and skills to drive decisive and transparent decision-making. Last, 85 percent of innovation leaders report that fear often or always holds their personnel back from innovation. A thriving workforce requires a cultural reset that catalyzes an outcomes orientation and a discovery mindset.
R&D organizations face a fierce battle for the most important skills, particularly in specialized areas such as AI and machine learning and in novel modalities such as cell and gene therapy. By strategically managing talent and creating a supportive environment, organizations can continue to drive innovation at the pace required to deliver on the promises of modern science.